Partnering
A balance that drives progress
In every successful collaboration, there exists a natural equilibrium—where aligned incentives, shared insights, and mutual respect converge to create outcomes greater than the sum of their parts.
At Arnatar Therapeutics, we approach partnerships through this lens. Just as the Nash equilibrium in game theory defines a stable state where no party benefits from changing strategy unilaterally, we believe true innovation arises when each contributor’s strengths are recognized and harmonized. In this balanced dynamic, we see the potential to redefine how therapies are discovered, developed, and delivered.
Unlocking potential through scientific synergy
Arnatar’s DARGERTM Platform integrates two powerful and proprietary technologies: a refined siRNA approach for selective gene downregulation and an innovative antisense oligonucleotide (ASO)-based method for gene expression upregulation to restore protein function. This dual approach empowers us to modulate gene expression with exceptional precision, opening the door to therapies for diseases once considered untreatable.
We recognize that collaboration can accelerate the advancement of our novel therapies, broaden the application of our platform, and bring transformative treatments to patients faster. Our scientific foundation is robust—but we understand that scale and impact are best achieved together. That’s why we welcome a range of partnership models including co-development, out-licensing, asset acquisitions, and other strategic alliances.